Table of Content

1. Introduction to Peptide Therapeutics
1.1 Overview of Peptide Therapeutics
1.2 Historical Perspective of Peptide Therapeutics
1.3 Classification Of Anti Cancer Peptides


2. Targets for Therapeutic Peptides
2.1 Signal Transduction Pathways
2.2 Cell Cycle Regulation
2.3 Cell Death Pathways
2.4 Tumor Suppressor Protein
2.5 Transcription Factors


3. Global Peptide Therapeutics Market Overview


4. Global Peptide Therapeutics Clinical Trials Overview
4.1 By Company
4.2 By Country
4.3 By Indication
4.4 By Patient Segment
4.5 By Phase


5. Insulin Clinical Pipeline By Company, Indication & Phase
5.1 Research
5.2 Preclinical
5.3 Phase-I
5.4 Phase-II
5.5 Phase-II/III
5.6 Phase-III
5.7 Preregistration
5.8 Registered
5.9 Marketed



6. Glucagon-like Peptides Clinical Pipeline By Company, Indication & Phase
6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-III
6.7 Preregistration
6.8 Marketed


7. Peptides Clinical Pipeline By Company, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Clinical Phase Unknown
7.4 Phase-I
7.5 Phase-I/II
7.6 Phase-II
7.7 Phase-II/III
7.8 Phase-III
7.9 Preregistration
7.12 Registered
7.11 Marketed


8. Cyclic Peptides Clinical Pipeline By Company, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Clinical Phase Unknown
8.4 Phase-I
8.5 Phase-II
8.6 Phase-III
8.7 Marketed


9. Multiple Peptides Clinical Pipeline By Company, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III
9.7 Preregistration
9.8 Registered
9.9 Marketed


10. Glycopeptides Clinical Pipeline By Company, Indication & Phase
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Preregistration
10.6 Marketed


11. Oligopeptides Clinical Pipeline By Company, Indication & Phase
11.1 Preclinical
11.2 Phase-I/II
11.3 Phase-II
11.4 Phase-II/III
11.5 Phase-III
11.6 Registered
11.7 Marketed



12. Lipopeptides Clinical Pipeline By Company, Indication & Phase
12.1 Research
12.2 Phase-II
12.3 Marketed


13. Dipeptides Clinical Pipeline By Company, Indication & Phase
13.1 Research
13.2 Phase-I
13.3 Phase-II
13.4 Phase-III
13.5 Registered
13.6 Marketed


14. Opioid Peptides Clinical Pipeline By Company, Indication & Phase
14.1 Research
14.2 Preclinical
14.3 Phase-I/II
14.4 Preregistration
14.5 Registered
14.6 Marketed


15. Depsipeptides Clinical Pipeline By Company, Indication & Phase
15.1 Preclinical
15.2 Phase-II
15.3 Registered
15.4 Marketed



16. Neuropeptides Clinical Pipeline By Company, Indication & Phase
16.1 Research
16.2 Preclinical
16.3 Phase-I/II
16.4 Phase-II
16.5 Marketed


17. Natriuretic Peptides Clinical Pipeline By Company, Indication & Phase
17.1 Phase-II
17.2 Marketed


18. Bicyclic Peptides Clinical Pipeline By Company, Indication & Phase
18.1 Preclinical


19. Competitive Landscape
19.1 Amgen
19.2 Amylin Pharmaceuticals
19.3 Apitope Technology
19.4 BioPartners
19.5 BiondVax Pharmaceuticals Ltd
19.6 Boehringer Ingelheim
19.7 Circassia
19.8 Corden Pharma (Peptisyntha)
19.9 Eli Lily
19.10 Galena Biopharmaceuticals
19.11 GlaxoSmithKline
19.12 Hyperion Therapeutics
19.13 ImmunoCellular Therapeutics
19.14 Ipsen
19.15 Lonza
19.16 Merck
19.17 NovoNordisk
19.18 Par Pharmaceuticals
19.19 PeptiDream
19.20 Roche
19.21 Sanofi
19.22 Tarix Pharmaceuticals

 



List of Figures

Figure 1-1: Classification of Anti-Cancer Peptides

Figure 2-1: Therapeutic Peptides Based on Their Biological Targets
Figure 2-2: MAPK Signaling Pathways
Figure 2-3: Cell Cycle in Eukaryotic
Figure 2-4: Cell Death Pathways
Figure 2-5: Features of Bcl-2 Family Proteins Including Anti-Apoptotic & Pro-Apoptotic

Figure 3-1: Global – Peptide Therapeutic Market (US$ Billion), 2020 - 2028
Figure 3-2: Global – Total Peptide Therapeutic Market Size vs. Cancer Peptide Therapeutic Market (US$ Billion), 2021
Figure 3-3: Global – Cancer Peptide Market Share in Total Peptide Market (%), 2021
Figure 3-4: Global – Cancer Peptide Drugs Market Size (US$ Billion), 2020 - 2028

Figure 4-1: Global - Peptide Drug Clinical Pipeline by Company (Number of Drugs), 2022 till 2028
Figure 4-2: Global - Peptide Drug Clinical Pipeline by Country (Number of Drugs), 2022 till 2028
Figure 4-3: Global - Peptide Drug Clinical Pipeline by Indication (Number of Drugs), 2022 till 2028
Figure 4-4: Global - Peptide Drug Clinical Pipeline by Patient Segment (Number of Drugs), 2022 till 2028
Figure 4-5: Global - Peptide Drug Clinical Pipeline by Phase (Number of Drugs), 2022 till 2028